CERo Therapeutics Holdings, Inc.
CERO
$9.46
$0.232.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.75% | 66.71% | 918.60% | 77.93% | 183.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.19% | 86.90% | 186.68% | 113.29% | 86.69% |
| Operating Income | -12.19% | -86.90% | -186.68% | -113.29% | -86.69% |
| Income Before Tax | -122.02% | 153.11% | -213.35% | -17.02% | 5.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -122.02% | 153.11% | -213.35% | -17.02% | 5.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.02% | 153.11% | -213.35% | -17.02% | 5.68% |
| EBIT | -12.19% | -86.90% | -186.68% | -113.29% | -86.69% |
| EBITDA | -13.34% | -98.60% | -201.96% | -119.02% | -91.06% |
| EPS Basic | 47.61% | -- | -581.15% | -143.08% | -143.08% |
| Normalized Basic EPS | 53.81% | -- | -- | -- | -- |
| EPS Diluted | 47.61% | -- | -581.15% | -143.08% | -143.08% |
| Normalized Diluted EPS | 53.81% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 9,396.04% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 9,396.04% | -- | 136.23% | -82.84% | -82.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |